CN113750050A - Method for preparing florfenicol solid dispersion through hot-melt extrusion - Google Patents
Method for preparing florfenicol solid dispersion through hot-melt extrusion Download PDFInfo
- Publication number
- CN113750050A CN113750050A CN202111192572.0A CN202111192572A CN113750050A CN 113750050 A CN113750050 A CN 113750050A CN 202111192572 A CN202111192572 A CN 202111192572A CN 113750050 A CN113750050 A CN 113750050A
- Authority
- CN
- China
- Prior art keywords
- florfenicol
- solid dispersion
- auxiliary materials
- preparing
- screw
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- AYIRNRDRBQJXIF-NXEZZACHSA-N (-)-Florfenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CF)NC(=O)C(Cl)Cl)C=C1 AYIRNRDRBQJXIF-NXEZZACHSA-N 0.000 title claims abstract description 63
- 229960003760 florfenicol Drugs 0.000 title claims abstract description 63
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims abstract description 21
- 238000009474 hot melt extrusion Methods 0.000 title claims description 18
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 26
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims abstract description 24
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 19
- 238000010438 heat treatment Methods 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 18
- 229940069328 povidone Drugs 0.000 claims abstract description 17
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 238000001125 extrusion Methods 0.000 claims abstract description 14
- 238000002156 mixing Methods 0.000 claims abstract description 14
- 238000001816 cooling Methods 0.000 claims abstract description 13
- 229920000858 Cyclodextrin Polymers 0.000 claims abstract description 12
- 239000001116 FEMA 4028 Substances 0.000 claims abstract description 12
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims abstract description 12
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims abstract description 12
- 229960004853 betadex Drugs 0.000 claims abstract description 12
- 238000007873 sieving Methods 0.000 claims abstract description 12
- 238000005520 cutting process Methods 0.000 claims abstract description 10
- 239000006069 physical mixture Substances 0.000 claims abstract description 10
- 239000000843 powder Substances 0.000 claims abstract description 10
- 239000004014 plasticizer Substances 0.000 claims abstract description 7
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000000969 carrier Substances 0.000 claims abstract description 3
- 238000002844 melting Methods 0.000 claims abstract description 3
- 230000008018 melting Effects 0.000 claims abstract description 3
- 229920003081 Povidone K 30 Polymers 0.000 claims description 7
- 229920001531 copovidone Polymers 0.000 claims description 7
- 229920003080 Povidone K 25 Polymers 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000136 polysorbate Polymers 0.000 claims description 2
- 238000002360 preparation method Methods 0.000 abstract description 5
- 239000003153 chemical reaction reagent Substances 0.000 abstract description 3
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 239000003814 drug Substances 0.000 description 14
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
- 229920000053 polysorbate 80 Polymers 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 229940093429 polyethylene glycol 6000 Drugs 0.000 description 5
- 229940079593 drug Drugs 0.000 description 4
- 241000700159 Rattus Species 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 229960005091 chloramphenicol Drugs 0.000 description 2
- WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 2
- 238000004090 dissolution Methods 0.000 description 2
- 239000012943 hotmelt Substances 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 108010077805 Bacterial Proteins Proteins 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- 230000021736 acetylation Effects 0.000 description 1
- 238000006640 acetylation reaction Methods 0.000 description 1
- XIWMTQIUUWJNRP-UHFFFAOYSA-N amidol Chemical compound NC1=CC=C(O)C(N)=C1 XIWMTQIUUWJNRP-UHFFFAOYSA-N 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 230000009477 glass transition Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000010094 polymer processing Methods 0.000 description 1
- 238000010008 shearing Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960003053 thiamphenicol Drugs 0.000 description 1
- OTVAEFIXJLOWRX-NXEZZACHSA-N thiamphenicol Chemical compound CS(=O)(=O)C1=CC=C([C@@H](O)[C@@H](CO)NC(=O)C(Cl)Cl)C=C1 OTVAEFIXJLOWRX-NXEZZACHSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Communicable Diseases (AREA)
Abstract
The invention discloses a preparation method of a florfenicol solid dispersion, which comprises the following steps: (1) respectively crushing the florfenicol serving as a raw material and auxiliary materials, sieving the crushed florfenicol and the auxiliary materials by a 40-100-mesh sieve, and fully mixing the crushed florfenicol and the auxiliary materials to prepare a physical mixture, wherein the auxiliary materials comprise beta-cyclodextrin, povidone carriers and plasticizers; (2) setting the extrusion temperature of different heating sections of the double-screw extruder to be not more than 160 ℃, starting the screw after the temperature is raised to a set value, wherein the rotating speed of the screw is 30-120 revolutions per minute, conveying the physical uniform-speed mixture prepared in the step (1) into the extruder, and finally extruding transparent yellow strips through material conveying, melting, mixing, homogenizing and cooling; (3) and cooling the extrudate, cutting into small segments, and crushing to obtain the florfenicol solid dispersion powder. The florfenicol solid dispersion prepared by the invention has the solubility of 2.8 percent, high bioavailability, simple process, easily obtained and safe reagents, low production cost and easy realization of industrialization.
Description
Technical Field
The invention relates to the field of pharmaceutical preparations, in particular to a preparation method of a florfenicol solid dispersion.
Background
The Hot-melt extrusion (HME) technology was first applied to the plastic and polymer processing industries, and since the 90 s of the 20 th century, the technology was introduced into the pharmaceutical industry and rapidly developed and applied. The HME technique is a technique in which a drug and a polymer excipient are simultaneously added to an extruder to mix, melt, and mold the drug and the excipient in a single extruder, and the multiphase state is converted into a single-phase state, and is widely used for preparing Solid Dispersions (SD), and the drug can be more uniformly dispersed in a carrier due to the strong mixing and shearing effects of the SD. The HME technology is mainly used for improving the water solubility, slow release, taste masking and the like of insoluble drugs and shows unique advantages. However, the technology is still rarely used in China, and no system research and application exist in the pharmaceutical industry.
Florfenicol belongs to amidol broad-spectrum antibacterial drugs and has strong antibacterial activity on various gram-positive bacteria, gram-negative bacteria, mycoplasma and the like. Florfenicol is mainly a bacteriostatic agent which inhibits the synthesis of bacterial proteins by binding with ribosome 50S subunit. Florfenicol has similar or stronger antibacterial activity to a plurality of microorganisms in vitro with chloramphenicol and thiamphenicol, and some bacteria which are resistant to chloramphenicol due to acetylation, such as escherichia coli, klebsiella pneumoniae and the like, can still be sensitive to the florfenicol. Pasteurella haemolytica, pasteurella multocida and actinobacillus pleuropneumoniae are highly sensitive to florfenicol. However, florfenicol has poor water solubility and low dissolution rate, and the application is greatly limited.
The water-soluble medicinal high-molecular solubilizer has good extrudability, high fluidity and wide application in inhibiting crystallization, and is particularly suitable for preparing solid dispersions by HME technology. Especially, the compound has a single glass transition temperature, so that the medicine exists in a carrier material in a molecular form in HME application, and the stability is better.
In order to improve the solubility and the dissolution rate of the florfenicol, the research adopts an HME technology, uses a high molecular auxiliary material with solubility enhancement as a carrier to prepare a florfenicol solid dispersion (FF-SD), inspects the solubility of the florfenicol solid dispersion, and performs in-vitro evaluation and pharmacokinetic research.
Disclosure of Invention
The invention provides the advantages of a method for preparing a solid dispersion by hot-melt extrusion, overcomes the defects of high quality and low cost of the traditional method and difficulty in fusion, and can maintain the stability of the medicine and improve the characteristics of the medicine such as solubility, bioavailability and the like.
The invention adopts the following technical scheme:
the invention provides a preparation method of hot-melt extruded florfenicol, which comprises the following steps:
(1) respectively crushing the florfenicol serving as a raw material and auxiliary materials, sieving the crushed florfenicol and the auxiliary materials by a 40-100-mesh sieve, and fully mixing the raw material and the auxiliary materials to prepare a physical mixture, wherein the auxiliary materials comprise beta-cyclodextrin, povidone carriers and plasticizers, and the auxiliary materials comprise:
20 percent of florfenicol,
30 to 40 percent of beta-cyclodextrin,
30 to 50 percent of polyvidone carrier,
0-15% of plasticizer;
(2) setting the extrusion temperature of different heating sections of the double-screw extruder to be not more than 160 ℃, starting the screw after the temperature is raised to a set value, wherein the rotating speed of the screw is 30-120 revolutions per minute, conveying the physical uniform-speed mixture prepared in the step (1) into the extruder, and finally extruding transparent yellow strips through material conveying, melting, mixing, homogenizing and cooling;
(3) and cooling the extrudate, cutting into small segments, and crushing to obtain the florfenicol solid dispersion powder.
Further, the povidone carrier in the step (1) is PVP-K30 and/or PVP-K25.
Further, the povidone carrier in the step (1) is PVP-K12 and/or copovidone s 630.
Further, the plasticizer in the step (1) is selected from one or more of polyethylene glycol and Tween.
Further, the extrusion temperature of the different heating sections in the step (2) is divided into 4 heating sections by the extruder.
Further, the extrusion temperatures of different heating sections of the twin-screw extruder in the step (2) are set to be not more than 160 ℃, and the temperatures of the 4 heating sections of the extruder are respectively as follows: 80-100 ℃, 120-150 ℃, 130-160 ℃ and 80-100 ℃.
Further, the step (3) is to crush the mixture and then pass the crushed mixture through a 80-100 mesh sieve.
Compared with the prior art, the invention has the following advantages and beneficial effects:
(1) the solubility of the florfenicol solid dispersion extruded by the hot-melt extrusion method can reach 2.8 percent, and the bioavailability of the florfenicol solid dispersion extruded by the hot-melt extrusion method is obviously higher than that of the florfenicol solid dispersion prepared by the conventional process;
(2) the method has the advantages of simple process, simple used equipment, easily obtained and safe reagents, low production cost and easy realization of industrialization.
Drawings
FIG. 1 is a plot of drug-time in plasma of SD rats after a single intramuscular injection of 25mg/kg of florfenicol.
Detailed Description
The invention will be further described with reference to specific examples, but the scope of the invention is not limited thereto:
in the invention, all reagents and raw materials can be purchased from the market or are commonly used in the industry, and the used methods are conventional methods in the field if no special description is provided.
The florfenicol raw material is a commercially available raw material.
Example 1
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (35%), povidone PVP-K30 (40%), copovidone S630 (9%) and Tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting extrusion temperatures of different heating sections of a double-screw extruder as follows: 80 ℃, 120 ℃, 130 ℃ and 80 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 50 revolutions per minute, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.84%.
Example 2
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (35%), povidone PVP-K25 (30%), copovidone S630 (9%), polyethylene glycol 6000 (5%) and Tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting the extrusion temperatures of different heating sections of a double-screw extruder as follows: 90 ℃, 125 ℃, 140 ℃ and 90 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 50 revolutions per minute, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.88 percent.
Example 3
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (40%), povidone PVP-K12 (30%), copovidone S630 (9%) and Tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting extrusion temperatures of different heating sections of a double-screw extruder as follows: 90 ℃, 130 ℃, 150 ℃ and 90 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 80 rpm, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.92 percent.
Example 4
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (30%), povidone PVP-K30 (20%), copovidone S630 (19%) and polyethylene glycol 6000 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting extrusion temperatures of different heating sections of a double-screw extruder as follows: 100 ℃, 140 ℃, 150 ℃ and 100 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 100 revolutions per minute, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.81 percent.
Example 5
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (35%), povidone PVP-K25 (20%), povidone PVP-K30 (23%), polyethylene glycol 6000 (1%) and Tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting the extrusion temperatures of different heating sections of a double-screw extruder as follows: 90 ℃, 135 ℃, 155 ℃ and 90 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 100 revolutions per minute, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.95 percent.
Example 6
Respectively crushing and screening raw material medicaments of florfenicol (20%), beta-cyclodextrin (40%), povidone PVP-K30 (20%), povidone PVP-K12 (18%), polyethylene glycol 6000 (1%) and Tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting the extrusion temperatures of different heating sections of a double-screw extruder as follows: 90 ℃, 125 ℃, 150 ℃ and 90 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 100 revolutions per minute, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.89%.
Example 7
Respectively crushing and sieving raw material medicaments of florfenicol (20%), beta-cyclodextrin (40%), povidone PVP-K30 (10%), povidone PVP-K12 (8%), copovidone S630 (16%), polyethylene glycol 6000 (5%) and tween 80 (1%) through a 100-mesh sieve, fully mixing to prepare a physical mixture, and setting extrusion temperatures of different heating sections of a double-screw extruder as follows: 100 ℃, 130 ℃, 150 ℃ and 90 ℃. And starting a screw after the temperature rises to a set value, wherein the rotation speed of the screw is 80 rpm, cutting the extrudate into small sections after cooling, crushing, and sieving by a 100-mesh sieve to obtain the florfenicol solid dispersion powder.
The florfenicol solid dispersion prepared by the embodiment has the room-temperature solubility of 2.94 percent.
The bioavailability of the hot melt extruded florfenicol solid dispersion (a) of the various embodiments of the present invention is significantly higher than the two products B and C that are commercially available, see fig. 1, table 1 and table 2.
Table 125 plasma concentration of florfenicol in SD rats plasma after single intramuscular injection of 125 mg/kg (n ═ 6):
table 225 pharmacokinetic parameters of florfenicol in SD rats after single dose intramuscular injection administration of mg/kg:
relative bioavailability:
relative bioavailability (F) ═ AUCT×DR)/(AUCR×DT)×100％
Note: t and R represent A/C preparation and B preparation, respectively, and D represents administration dosage
FA/B＝157.6％
FC/B＝107.5％。
Claims (7)
1. A method for preparing florfenicol solid dispersion by hot melt extrusion is characterized by comprising the following steps: the method comprises the following steps:
(1) respectively crushing the florfenicol serving as a raw material and auxiliary materials, sieving the crushed florfenicol and the auxiliary materials by a 40-100-mesh sieve, and fully mixing the raw material and the auxiliary materials to prepare a physical mixture, wherein the auxiliary materials comprise beta-cyclodextrin, povidone carriers and plasticizers, and the auxiliary materials comprise:
20 percent of florfenicol,
30 to 40 percent of beta-cyclodextrin,
30 to 50 percent of polyvidone carrier,
0-15% of plasticizer;
(2) setting the extrusion temperature of different heating sections of the double-screw extruder to be not more than 160 ℃, starting the screw after the temperature is raised to a set value, wherein the rotating speed of the screw is 30-120 revolutions per minute, conveying the physical uniform-speed mixture prepared in the step (1) into the extruder, and finally extruding transparent yellow strips through material conveying, melting, mixing, homogenizing and cooling;
(3) and cooling the extrudate, cutting into small segments, and crushing to obtain the florfenicol solid dispersion powder.
2. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: the povidone carrier in the step (1) is PVP-K30 and/or PVP-K25.
3. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: the povidone carrier in the step (1) is PVP-K12 and/or copovidone s 630.
4. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: in the step (1), the plasticizer is selected from one or more of polyethylene glycol and Tween.
5. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: and (3) dividing the extruder into 4 heating sections at the different heating section extrusion temperatures in the step (2).
6. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: the extrusion temperatures of different heating sections of the double-screw extruder in the step (2) are set to be not more than 160 ℃, and the temperatures of 4 heating sections of the extruder are respectively as follows: 80-100 ℃, 120-150 ℃, 130-160 ℃ and 80-100 ℃.
7. The method for preparing the florfenicol solid dispersion by hot melt extrusion as claimed in claim 1, wherein: and (4) crushing in the step (3), and sieving by 80-100 meshes after crushing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111192572.0A CN113750050A (en) | 2021-10-13 | 2021-10-13 | Method for preparing florfenicol solid dispersion through hot-melt extrusion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202111192572.0A CN113750050A (en) | 2021-10-13 | 2021-10-13 | Method for preparing florfenicol solid dispersion through hot-melt extrusion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN113750050A true CN113750050A (en) | 2021-12-07 |
Family
ID=78799306
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202111192572.0A Pending CN113750050A (en) | 2021-10-13 | 2021-10-13 | Method for preparing florfenicol solid dispersion through hot-melt extrusion |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113750050A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848596A (en) * | 2022-06-20 | 2022-08-05 | 浙江大学 | Preparation method of traditional Chinese medicine molten mixture |
| CN116019771A (en) * | 2022-09-09 | 2023-04-28 | 沈阳伟嘉生物技术有限公司 | Florfenicol miscible beverage amorphous solid dispersion preparation, and preparation method and application thereof |
| CN116270475A (en) * | 2023-02-06 | 2023-06-23 | 爱力迈(安徽)动物药业有限公司 | Preparation method of baicalin hot-melt extrusion soluble powder |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657614A (en) * | 2012-05-03 | 2012-09-12 | 青岛绿曼生物工程有限公司 | Method for preparing solid florfenicol dispersion |
| CN102973489A (en) * | 2012-12-11 | 2013-03-20 | 江西新世纪民星动物保健品有限公司 | Florfenicol solid dispersoid and preparation method thereof |
| CN111643456A (en) * | 2020-07-03 | 2020-09-11 | 杭州爱力迈动物药业有限公司 | Preparation method and application of florfenicol solid dispersion with high dissolution rate |
-
2021
- 2021-10-13 CN CN202111192572.0A patent/CN113750050A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102657614A (en) * | 2012-05-03 | 2012-09-12 | 青岛绿曼生物工程有限公司 | Method for preparing solid florfenicol dispersion |
| CN102973489A (en) * | 2012-12-11 | 2013-03-20 | 江西新世纪民星动物保健品有限公司 | Florfenicol solid dispersoid and preparation method thereof |
| CN111643456A (en) * | 2020-07-03 | 2020-09-11 | 杭州爱力迈动物药业有限公司 | Preparation method and application of florfenicol solid dispersion with high dissolution rate |
Non-Patent Citations (2)
| Title |
|---|
| 闫浩松: "氟苯尼考新型粉剂的制备及其质量评价", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 * |
| 高涛等主编: "《药剂学》", 31 May 2017, 延边大学出版社 * |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114848596A (en) * | 2022-06-20 | 2022-08-05 | 浙江大学 | Preparation method of traditional Chinese medicine molten mixture |
| CN116019771A (en) * | 2022-09-09 | 2023-04-28 | 沈阳伟嘉生物技术有限公司 | Florfenicol miscible beverage amorphous solid dispersion preparation, and preparation method and application thereof |
| CN116270475A (en) * | 2023-02-06 | 2023-06-23 | 爱力迈(安徽)动物药业有限公司 | Preparation method of baicalin hot-melt extrusion soluble powder |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113750050A (en) | Method for preparing florfenicol solid dispersion through hot-melt extrusion | |
| US10213948B2 (en) | Hot melt fragmentation extruder and process | |
| EP2531176B1 (en) | Preparation of a powdery pharmaceutical composition by means of an extruder | |
| DK2876130T3 (en) | PROCEDURE FOR THE PREPARATION OF A SELF-STRENGTHED STARCH COMPOSITION USED FOR Capsule Preparation | |
| KR20160086382A (en) | Formulation of sparingly soluble compounds by hot-melt extrusion | |
| CN102204868B (en) | Hot-melt extrusion process for preparing indometacin quick release preparation from multi-element auxiliary materials | |
| CN109195588B (en) | Use of aminosugars as plasticizers | |
| CN1695600A (en) | Method for preparing components, capsules and capsule wall material of combination of natural polysaccharide macromolecules | |
| CN111643456A (en) | Preparation method and application of florfenicol solid dispersion with high dissolution rate | |
| CN102528965A (en) | Method for producing granulates containing at least one water-soluble component | |
| EP3445558B1 (en) | Fractional lobe processor, and related process for hot melt extrusion | |
| CN112206213A (en) | Sildenafil citrate composition and preparation method thereof | |
| CN109464398B (en) | Preparation method of carbamazepine solid dispersion with high drug loading capacity | |
| CN109481411B (en) | Hot-melt extrusion solid dispersion of nimodipine and preparation method of tablet thereof | |
| CN109730967B (en) | Nifedipine solid dispersion and preparation method thereof | |
| CN104208072A (en) | Megestrol acetate hot-melt extrusion preparation | |
| CN112402433A (en) | Metformin-glibenclamide composition and preparation method thereof | |
| AU2014271228B2 (en) | Preparation process of a self-reinforced starch composite used to produce capsules | |
| CA2872054C (en) | Preparation process of a self-reinforced starch composite used to produce capsules | |
| Maniruzzaman et al. | Hot-melt extrusion: a versatile technology | |
| Danilova et al. | Hot Melt Extrusion Technology as a Modern Strategy for Improving the Bioavailability of Flavonoids | |
| Almutairi | Novel Perspectives of Hot Melt Extrusion Technology for Pharmaceutical Applications | |
| CN116869958A (en) | Vinegar willow flavone solid dispersion, solid preparation and preparation method | |
| PANDYA | PHARMACEUTICAL APPLICATIONS OF HOT MELT EXTRUSION TECHNOLOGY |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20211207 |
|
| WD01 | Invention patent application deemed withdrawn after publication |